Aldehyde dehydrogenase 2 activity and aldehydic load contribute to neuroinflammation and Alzheimer's disease related pathology.


Journal

Acta neuropathologica communications
ISSN: 2051-5960
Titre abrégé: Acta Neuropathol Commun
Pays: England
ID NLM: 101610673

Informations de publication

Date de publication:
12 12 2019
Historique:
received: 20 09 2019
accepted: 29 10 2019
entrez: 13 12 2019
pubmed: 13 12 2019
medline: 26 9 2020
Statut: epublish

Résumé

Aldehyde dehydrogenase 2 deficiency (ALDH2*2) causes facial flushing in response to alcohol consumption in approximately 560 million East Asians. Recent meta-analysis demonstrated the potential link between ALDH2*2 mutation and Alzheimer's Disease (AD). Other studies have linked chronic alcohol consumption as a risk factor for AD. In the present study, we show that fibroblasts of an AD patient that also has an ALDH2*2 mutation or overexpression of ALDH2*2 in fibroblasts derived from AD patients harboring ApoE ε4 allele exhibited increased aldehydic load, oxidative stress, and increased mitochondrial dysfunction relative to healthy subjects and exposure to ethanol exacerbated these dysfunctions. In an in vivo model, daily exposure of WT mice to ethanol for 11 weeks resulted in mitochondrial dysfunction, oxidative stress and increased aldehyde levels in their brains and these pathologies were greater in ALDH2*2/*2 (homozygous) mice. Following chronic ethanol exposure, the levels of the AD-associated protein, amyloid-β, and neuroinflammation were higher in the brains of the ALDH2*2/*2 mice relative to WT. Cultured primary cortical neurons of ALDH2*2/*2 mice showed increased sensitivity to ethanol and there was a greater activation of their primary astrocytes relative to the responses of neurons or astrocytes from the WT mice. Importantly, an activator of ALDH2 and ALDH2*2, Alda-1, blunted the ethanol-induced increases in Aβ, and the neuroinflammation in vitro and in vivo. These data indicate that impairment in the metabolism of aldehydes, and specifically ethanol-derived acetaldehyde, is a contributor to AD associated pathology and highlights the likely risk of alcohol consumption in the general population and especially in East Asians that carry ALDH2*2 mutation.

Identifiants

pubmed: 31829281
doi: 10.1186/s40478-019-0839-7
pii: 10.1186/s40478-019-0839-7
pmc: PMC6907112
doi:

Substances chimiques

Aldehydes 0
Ethanol 3K9958V90M
ALDH2 protein, human EC 1.2.1.3
Aldehyde Dehydrogenase, Mitochondrial EC 1.2.1.3

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

190

Subventions

Organisme : NIAAA NIH HHS
ID : R01 AA011147
Pays : United States
Organisme : NIDDK NIH HHS
ID : T32 DK098132
Pays : United States

Références

Nat Neurosci. 2019 Oct;22(10):1635-1648
pubmed: 31551592
J Immunol. 2009 Oct 1;183(7):4733-44
pubmed: 19752239
BMJ. 2018 Aug 1;362:k2927
pubmed: 30068508
Sci Transl Med. 2014 Aug 27;6(251):251ra118
pubmed: 25163478
Lancet Neurol. 2019 Jan;18(1):88-106
pubmed: 30497964
Int J Environ Res Public Health. 2010 Dec;7(12):4281-304
pubmed: 21318009
J Neurol Sci. 2008 May 15;268(1-2):172-5
pubmed: 18201725
Brain Res. 2007 Oct 31;1178:28-37
pubmed: 17888892
Proc Natl Acad Sci U S A. 2015 Mar 10;112(10):3074-9
pubmed: 25713355
Free Radic Biol Med. 2012 Sep 15;53(6):1371-80
pubmed: 22885031
Neurochem Res. 2016 May;41(5):1029-34
pubmed: 26646001
Alcohol Res Health. 2003;27(4):277-84
pubmed: 15540798
Exp Neurobiol. 2015 Dec;24(4):325-40
pubmed: 26713080
Mol Neurobiol. 2018 Jun;55(6):5006-5018
pubmed: 28799137
Science. 1992 Apr 10;256(5054):184-5
pubmed: 1566067
Redox Biol. 2018 Apr;14:450-464
pubmed: 29080524
Cancer Epidemiol Biomarkers Prev. 2016 Apr;25(4):693-9
pubmed: 26827895
PLoS Med. 2009 Mar 24;6(3):e50
pubmed: 19320537
Front Neurosci. 2017 Oct 06;11:553
pubmed: 29056898
Science. 2008 Sep 12;321(5895):1493-5
pubmed: 18787169
Biochim Biophys Acta. 2010 Jan;1802(1):198-204
pubmed: 19616093
J Clin Invest. 1999 Sep;104(6):805-13
pubmed: 10491416
J Biomed Sci. 2017 Jul 19;24(1):47
pubmed: 28720101
Front Neurol. 2019 Mar 28;10:290
pubmed: 30984100
Mol Brain. 2015 Apr 25;8:27
pubmed: 25910195
J Neurochem. 1997 May;68(5):2092-7
pubmed: 9109537
Biochem Biophys Res Commun. 2000 Jun 24;273(1):192-6
pubmed: 10873585
J Clin Invest. 2013 Dec;123(12):5371-88
pubmed: 24231356
Brain Sci. 2016 Aug 16;6(3):null
pubmed: 27537918
Addiction. 2009 Apr;104(4):533-50
pubmed: 19335652
J Alzheimers Dis. 2018;62(3):1403-1416
pubmed: 29036828
J Neurosci. 2008 Jun 11;28(24):6239-49
pubmed: 18550766
J Neurol Sci. 1998 Apr 1;156(2):172-6
pubmed: 9588853
Curr Alzheimer Res. 2010 Dec;7(8):656-64
pubmed: 20678074
Front Behav Neurosci. 2013 Jul 17;7:87
pubmed: 23882197
Clin Liver Dis. 2012 Nov;16(4):667-85
pubmed: 23101976
Open Biol. 2017 Dec;7(12):
pubmed: 29237809
Lancet. 2018 Sep 22;392(10152):1015-1035
pubmed: 30146330
Biochim Biophys Acta. 2014 Aug;1842(8):1240-7
pubmed: 24189435
Curr Neuropharmacol. 2009 Mar;7(1):65-74
pubmed: 19721819
Alcohol Res Health. 2007;30(1):5-13
pubmed: 17718394
Biochemistry. 2007 Feb 13;46(6):1503-10
pubmed: 17279615
Science. 2009 Apr 3;324(5923):102-5
pubmed: 19342591
Biochim Biophys Acta. 2010 Aug;1801(8):924-9
pubmed: 20176130
EMBO Mol Med. 2018 Mar;10(3):
pubmed: 29335339
Redox Biol. 2015;4:193-9
pubmed: 25598486
Eur Heart J. 2012 Apr;33(7):829-37, 837a-837d
pubmed: 21890489
Pharmacol Rep. 2016 Feb;68(1):127-38
pubmed: 26721364
Oncotarget. 2017 Dec 22;9(5):6128-6143
pubmed: 29464060
Neurobiol Aging. 2002 Sep-Oct;23(5):655-64
pubmed: 12392766
Int J Alzheimers Dis. 2011 Mar 15;2011:925050
pubmed: 21461357
Sci Transl Med. 2014 Sep 24;6(255):255ra130
pubmed: 25253673
Immunol Cell Biol. 2011 Aug;89(6):716-27
pubmed: 21221123
Cardiovasc Res. 2014 Sep 1;103(4):498-508
pubmed: 24817685
Exp Anim. 2009 Apr;58(2):141-9
pubmed: 19448337
Biochim Biophys Acta Mol Basis Dis. 2017 Nov;1863(11):2942-2953
pubmed: 28668332
Neurobiol Aging. 2006 Aug;27(8):1094-9
pubmed: 15993986
J Clin Invest. 1995 Nov;96(5):2180-6
pubmed: 7593603
Alcohol Clin Exp Res. 2016 Sep;40(9):1802-16
pubmed: 27476876
J Exp Med. 2011 Mar 14;208(3):417-20
pubmed: 21357740

Auteurs

Amit U Joshi (AU)

Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, CA, USA.

Lauren D Van Wassenhove (LD)

Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, CA, USA.

Kelsey R Logas (KR)

Division of Stem Cell Biology and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.

Paras S Minhas (PS)

Department of Neurology & Neurological Sciences, Stanford School of Medicine, Stanford, CA, USA.

Katrin I Andreasson (KI)

Department of Neurology & Neurological Sciences, Stanford School of Medicine, Stanford, CA, USA.

Kenneth I Weinberg (KI)

Division of Stem Cell Biology and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.

Che-Hong Chen (CH)

Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, CA, USA.

Daria Mochly-Rosen (D)

Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, CA, USA. mochly@stanford.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH